NCT00023712View on ClinicalTrials.gov

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 5, 2001

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG

bortezomib

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00023712 - Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter